ARTICLE | Company News
Par ends Advancis Amoxicillin Pulsys deal
August 4, 2005 12:31 AM UTC
PRX ended its 2004 deal with AVNC to develop and market Amoxicillin Pulsys after the compound failed two Phase III trials to treat pharyngitis/tonsillitis (see BioCentury Extra, Thursday July 21, 20...